Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387432822> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4387432822 endingPage "200" @default.
- W4387432822 startingPage "190" @default.
- W4387432822 abstract "The main goal of this article is to present the results of the synthesis of new alkyl derivatives of 5-(2-bromo4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole-3-thiol and molecular docking studies against COX-1 and COX-2. Previous studies have established a wide range of biological activity of 1,2,4-triazole derivatives. Therefore, it was essential to determine how a new series of 1,2,4-triazole derivatives would provide potential anti-inflammatory activity. To reach the goal, raw alkyl derivatives of 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole-3-thiols (2a-2i) from 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole3-thiol (1e) were obtained. The structure of the synthesized compounds was confirmed by 1H-NMR elemental analyses. The individuality and purity of compounds were confirmed by the method of liquid chromatography-mass spectrometry. These compounds have a relatively simple synthesis scheme, which gives them an advantage in creating a potential drug, and the appearance of alkyl radicals in the molecule should positively affect pharmacokinetic indicators, stability, selectivity, and bioavailability. An in silico study was conducted for the synthesized compounds, namely molecular docking, in relation to the interaction with COX-1 and COX-2. Based on the selectivity indexes of binding modes observed for the selected compounds (2e, 2g) with active COX-1 centers, it was found that compounds can reliably exhibit their anti-inflammatory effect through the prostaglandin biosynthesis pathway, inhibiting COX-1 instead of COX-2. The effect of hydrophobic interactions of alkyl groups of 1,2,4-triazole derivatives on changes in affinity and selectivity to COX-1 or COX-2 has also been proven. Therefore, derivatives of 1,2,4 are promising candidates for improvement, further study, and future development of new, more powerful antiinflammatory drugs for therapeutic use." @default.
- W4387432822 created "2023-10-09" @default.
- W4387432822 creator A5010937083 @default.
- W4387432822 creator A5045351010 @default.
- W4387432822 creator A5051852237 @default.
- W4387432822 creator A5072696879 @default.
- W4387432822 creator A5086176219 @default.
- W4387432822 creator A5087187773 @default.
- W4387432822 creator A5089846530 @default.
- W4387432822 date "2023-01-01" @default.
- W4387432822 modified "2023-10-14" @default.
- W4387432822 title "Synthesis, characterization, molecular docking studies of new alkyl derivatives of 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H- -1,2,4-triazole-3-thiol." @default.
- W4387432822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37805265" @default.
- W4387432822 hasPublicationYear "2023" @default.
- W4387432822 type Work @default.
- W4387432822 citedByCount "0" @default.
- W4387432822 crossrefType "journal-article" @default.
- W4387432822 hasAuthorship W4387432822A5010937083 @default.
- W4387432822 hasAuthorship W4387432822A5045351010 @default.
- W4387432822 hasAuthorship W4387432822A5051852237 @default.
- W4387432822 hasAuthorship W4387432822A5072696879 @default.
- W4387432822 hasAuthorship W4387432822A5086176219 @default.
- W4387432822 hasAuthorship W4387432822A5087187773 @default.
- W4387432822 hasAuthorship W4387432822A5089846530 @default.
- W4387432822 hasConcept C104317684 @default.
- W4387432822 hasConcept C118792377 @default.
- W4387432822 hasConcept C159110408 @default.
- W4387432822 hasConcept C161790260 @default.
- W4387432822 hasConcept C178790620 @default.
- W4387432822 hasConcept C185592680 @default.
- W4387432822 hasConcept C21951064 @default.
- W4387432822 hasConcept C2775905019 @default.
- W4387432822 hasConcept C2777907353 @default.
- W4387432822 hasConcept C2780020378 @default.
- W4387432822 hasConcept C2780263894 @default.
- W4387432822 hasConcept C2781002465 @default.
- W4387432822 hasConcept C41685203 @default.
- W4387432822 hasConcept C55493867 @default.
- W4387432822 hasConcept C71240020 @default.
- W4387432822 hasConcept C71924100 @default.
- W4387432822 hasConceptScore W4387432822C104317684 @default.
- W4387432822 hasConceptScore W4387432822C118792377 @default.
- W4387432822 hasConceptScore W4387432822C159110408 @default.
- W4387432822 hasConceptScore W4387432822C161790260 @default.
- W4387432822 hasConceptScore W4387432822C178790620 @default.
- W4387432822 hasConceptScore W4387432822C185592680 @default.
- W4387432822 hasConceptScore W4387432822C21951064 @default.
- W4387432822 hasConceptScore W4387432822C2775905019 @default.
- W4387432822 hasConceptScore W4387432822C2777907353 @default.
- W4387432822 hasConceptScore W4387432822C2780020378 @default.
- W4387432822 hasConceptScore W4387432822C2780263894 @default.
- W4387432822 hasConceptScore W4387432822C2781002465 @default.
- W4387432822 hasConceptScore W4387432822C41685203 @default.
- W4387432822 hasConceptScore W4387432822C55493867 @default.
- W4387432822 hasConceptScore W4387432822C71240020 @default.
- W4387432822 hasConceptScore W4387432822C71924100 @default.
- W4387432822 hasIssue "4" @default.
- W4387432822 hasLocation W43874328221 @default.
- W4387432822 hasOpenAccess W4387432822 @default.
- W4387432822 hasPrimaryLocation W43874328221 @default.
- W4387432822 hasRelatedWork W1979772102 @default.
- W4387432822 hasRelatedWork W2041734647 @default.
- W4387432822 hasRelatedWork W2050011640 @default.
- W4387432822 hasRelatedWork W2090541219 @default.
- W4387432822 hasRelatedWork W2104601648 @default.
- W4387432822 hasRelatedWork W2107258110 @default.
- W4387432822 hasRelatedWork W2291002887 @default.
- W4387432822 hasRelatedWork W2351797621 @default.
- W4387432822 hasRelatedWork W2506855304 @default.
- W4387432822 hasRelatedWork W3037787637 @default.
- W4387432822 hasVolume "72" @default.
- W4387432822 isParatext "false" @default.
- W4387432822 isRetracted "false" @default.
- W4387432822 workType "article" @default.